Preparation and preclinical evaluation of 66Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 109-114

  Lopez Rodriguez, V ^a   Gaspar Carcamo, R E ^a   Pedraza Lopez, M ^b   Rojas Calderon, E L ^c   Arteaga de Murphy, C ^b   Ferro Flores, G ^c   Avila Rodriguez, M A ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

Author keywords

Angiogenesis; Gallium 66; Integrin v 3; PET imaging; RGD peptides; Theranostics

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; TETRAXETAN GLUTAMYLCYCLOARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE GA 66; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; CYCLIC (ARGINYL-GLYCYL-ASPARTYL-PHENYLALANYL-LYSYL); CYCLOPEPTIDE; GALLIUM; SINGLE HETEROCYCLIC RINGS; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSIMETRY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG PURITY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; PROTEIN BINDING; RADIOTHERAPY; RAT; THERANOSTICS; THIN LAYER CHROMATOGRAPHY; TUMOR XENOGRAFT; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DIAGNOSTIC USE; GLIOMA; METABOLISM; PATHOLOGY; RADIOCHEMISTRY; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GALLIUM RADIOISOTOPES; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; INTEGRIN ALPHAVBETA3; MICE; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; TISSUE DISTRIBUTION;

EID: 84921291121     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.09.010     Document Type: Article

References (39)

1. Kai C., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62:1005-1022.
2. Tolmachev V., Stone-Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochim Biophys Acta 1800, 2010:487-510.
3. Lee S., Xie J., Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010, 110:3087-3111.
4. Schottelius M., Wester H.J. Molecular imaging targeting peptide receptors. Methods 2009, 48:161-177.
5. Kaur S., Venktaraman G., Jain M., Senapati S., Garg P.K., Batra S.K. Recent trends in antibody-based oncologic imaging. Cancer Lett 2012, 315:97-111.
6. Plow E.F., Haas T.A., Zhang L., Loftusi J., Smith J.W. Ligand binding to integrins. J Biol Chem 2000, 275:21785-21788.
7. Gurrath M., Muller G., Kessler H., Aumailley M., Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992, 210:911-921.
8. 5 antagonist, rapidly detects spontaneous tumors in mice and dogs. Nucl Med Commun 2000, 21:564.
9. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S., et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002, 62:6146-6151.
10. Janssen M.L., Oyen W.J., Massuger L.F., Frielink C., Dijkgraaf I., Edwards D.S., et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002, 17:641-646.
11. Janssen M.L., Frielink C., Dijkgraaf I., Oyen W.J., Edwards D.S., Liu S., et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm 2004, 19:399-404.
12. 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011, 38:128-137.
13. 64Cu-labeled dimeric RGD péptidos. Mol Imaging Biol 2004, 6:350-359.
14. 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
15. Lewis M.R., Reichert D.E., Laforest R., Margenau W.H., Shefer R.E., Klinkowstein R.E., et al. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. Nucl Med Biol 2002, 29:701-706.
16. 66Ga as an isotope for PET imaging and quantification. Med Phys 1997, 24:317-326.
17. 3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002, 29:147-157.
18. Janib S.M., Moses A.S., MacKay J.A. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010, 62:1052-1063.
19. 66/68Ga from zinc targets for PET. Appl Radiat Isot 2012, 70:1792-1796.
20. Kubíčeck Vojtěch, Havlíčkova Jana, Kotek Jan, Tircsó Gyula, Hermann Pert, Tóth Éva, et al. Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. Inorg Chem 2010, 49:10960-10969.
21. 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol 2012, 39:777-784.
22. Petty C. Research Techniques in the Rats 1982, Charles C. Thomas, Springfield, IL.
23. Frank D.W. Physiological data of laboratory animals 1976, CRC Press, Boca Raton, FL.
24. Jimenez-Mancilla N.P., Ferro-Flores G., Ocampo-García B., Luna-Gutiérrez M., Pedraza-Lopez M., Torres-Garcia E. Multifunctional targeted radiotherapy system for induced tumours expressing gastrin-releasing peptide receptor. Curr Nanosci 2012, 8:193-201.
25. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(v)β(3) integrins. J Labelled Comp Radiopharm 2012, 50:140-148.
26. 177Lu radionuclides. Cancer Biother Radiopharm 2005, 20:436-449.
27. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46:1023-1027.
28. 2. J Nucl Med 2006, 47:113-121.
29. 68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
30. 3 integrin expression: synthesis, evaluation, and comparison. Nucl Med Biol 2013, 40:65-72.
31. 3 integrin expression. Eur J Nucl Med Mol Imaging 2008, 35:1507-1515.
32. 68Ga-agents. Appl Radiat Isot 2013, 76:14-23.
33. 2; in vivo imaging studies in human xenograft tumors. Nucl Med Biol 2014, 41:259-267.
34. 3 expression. Eur J Nucl Med Mol Imaging 2008, 35:1100-1108.
35. 177Lu-labeled cyclic RGD peptide dimer. Nucl Med Biol 2013, 40:946-954.
36. 3 receptor-positive tumor targeting. J Labelled Comp Radiopharm 2012, 55:10-17.
37. 177Lu-Labeled RGD derivative for targeting angiogenesis. Cancer Biother Radiopharm 2010, 25:687-691.
38. Fawwaz R.A., Wang T.S., Srivastava S.C., Hardy M.A. The use of radionuclides for tumor therapy. Int J Rad Appl Instrum B 1986, 13:429-436.
39. Zaknun J., Bodei L., Mueller-Brand J., Pavel M.E., Baum R.P., Hörsch D., et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013, 40:800-816.